GLP-1 weight-loss drugs like Ozempic or SGLT2 diabetes medications like Jardiance or Farxiga both helped protect the health ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...

Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may protect the kidneys better than glucagon-like peptide 1 receptor ...

On Thursday, members of the Endocrinologic and Metabolic Drugs Advisory Committee will help the FDA decide whether the ...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity.

A recent case report highlights the importance of understanding the possibility of the development of Euglycemic diabetic ...

A collaboration of researchers led by Emory University Rollins School of Public Health, Atlanta, is urging caution when ...

Patients with broad range of kidney function show reduced effects following discontinuation after EMPA-KIDNEY trial.